ASX - By Stock
|
SPL |
Re:
Mundipharma and Astodrimer sodium
|
|
Dtbo365
|
2 |
756 |
3 |
27/04/24 |
27/04/24 |
ASX - By Stock
|
2
|
756
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Could this happen to Viraleze with marketing approval
|
|
Dtbo365
|
29 |
5.3K |
1 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
29
|
5.3K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
The blackout period remains in place
|
|
Dtbo365
|
18 |
3.2K |
4 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
18
|
3.2K
|
4
|
|
ASX - By Stock
|
LGP |
Re:
Ann: Germany Legalises Cannabis
|
|
Dtbo365
|
11 |
4.5K |
2 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
11
|
4.5K
|
2
|
|
ASX - By Stock
|
SPL Medicine |
Re:
TGA STAFF SICK - Delayed Interim decision re Scheduling Astodrimer sodium as Nasal Spray
|
|
Dtbo365
|
8 |
2.3K |
2 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
8
|
2.3K
|
2
|
|
ASX - By Stock
|
LGP |
Re:
Ann: Germany Legalises Cannabis
|
|
Dtbo365
|
11 |
4.5K |
1 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
11
|
4.5K
|
1
|
|
ASX - By Stock
|
LGP |
Re:
Ann: Reset Offers withdrawn and Reset to remain LGP subsidiary
|
|
Dtbo365
|
10 |
4.2K |
0 |
24/02/24 |
24/02/24 |
ASX - By Stock
|
10
|
4.2K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VivaGel BV US FDA Appeal Outcome
|
|
Dtbo365
|
60 |
13K |
2 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
60
|
13K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Biosure nasal spray
|
|
Dtbo365
|
37 |
6.2K |
1 |
20/01/24 |
20/01/24 |
ASX - By Stock
|
37
|
6.2K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Biosure nasal spray
|
|
Dtbo365
|
37 |
6.2K |
2 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
37
|
6.2K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Jeremy Paull Safety and Tolerability in humans
|
|
Dtbo365
|
20 |
4.0K |
4 |
13/01/24 |
13/01/24 |
ASX - By Stock
|
20
|
4.0K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
New CEO’s focus
|
|
Dtbo365
|
85 |
19K |
2 |
08/01/24 |
08/01/24 |
ASX - By Stock
|
85
|
19K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VIRALEZ UK COVID-19 Clinical Study Completes Recruitment
|
|
Dtbo365
|
50 |
13K |
2 |
11/12/23 |
11/12/23 |
ASX - By Stock
|
50
|
13K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Expectats for October
|
|
Dtbo365
|
53 |
12K |
1 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
53
|
12K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Expectats for October
|
|
Dtbo365
|
53 |
12K |
1 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
53
|
12K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
TGA consultations open until 29 Sept astodrimer
|
|
Dtbo365
|
10 |
2.7K |
1 |
30/09/23 |
30/09/23 |
ASX - By Stock
|
10
|
2.7K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Positive DEP irinotecan clinical results presentation
|
|
Dtbo365
|
56 |
14K |
2 |
13/09/23 |
13/09/23 |
ASX - By Stock
|
56
|
14K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Another fluff up from the Chairman
|
|
Dtbo365
|
3 |
1.2K |
0 |
27/08/23 |
27/08/23 |
ASX - By Stock
|
3
|
1.2K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
SPL chart
|
|
Dtbo365
|
451 |
139K |
6 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
451
|
139K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Trading Halt
|
|
Dtbo365
|
146 |
45K |
0 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
146
|
45K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Trading Halt
|
|
Dtbo365
|
146 |
45K |
0 |
30/07/23 |
30/07/23 |
ASX - By Stock
|
146
|
45K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Heparin nasal spray trial in Melbourne
|
|
Dtbo365
|
32 |
6.1K |
1 |
17/07/23 |
17/07/23 |
ASX - By Stock
|
32
|
6.1K
|
1
|
|
ASX - By Stock
|
LGP |
Re:
Ann: LGP Awarded French trial tender for CBD50
|
|
Dtbo365
|
3 |
1.5K |
1 |
12/07/23 |
12/07/23 |
ASX - By Stock
|
3
|
1.5K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Smear Campains Undermine Share Value
|
|
Dtbo365
|
61 |
16K |
1 |
18/06/23 |
18/06/23 |
ASX - By Stock
|
61
|
16K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Smear Campains Undermine Share Value
|
|
Dtbo365
|
61 |
16K |
2 |
17/06/23 |
17/06/23 |
ASX - By Stock
|
61
|
16K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma CEO to retire in 2024
|
|
Dtbo365
|
69 |
26K |
3 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
69
|
26K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma CEO to retire in 2024
|
|
Dtbo365
|
69 |
26K |
1 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
69
|
26K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Garlic
|
|
Dtbo365
|
16 |
3.3K |
0 |
01/06/23 |
01/06/23 |
ASX - By Stock
|
16
|
3.3K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Is Accumulation occurring
|
|
Dtbo365
|
30 |
6.7K |
0 |
24/05/23 |
24/05/23 |
ASX - By Stock
|
30
|
6.7K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Animal Studies are crucial as a precursor to human clinical trials
|
|
Dtbo365
|
10 |
2.5K |
3 |
19/05/23 |
19/05/23 |
ASX - By Stock
|
10
|
2.5K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Mckesson UK and AURELIUS
|
|
Dtbo365
|
107 |
24K |
2 |
25/04/23 |
25/04/23 |
ASX - By Stock
|
107
|
24K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
New TGA rules on nanoparticles for medical devices
|
|
Dtbo365
|
28 |
8.0K |
0 |
08/04/23 |
08/04/23 |
ASX - By Stock
|
28
|
8.0K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
If you're not happy
|
|
Dtbo365
|
15 |
3.7K |
2 |
04/04/23 |
04/04/23 |
ASX - By Stock
|
15
|
3.7K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Mckesson UK and AURELIUS
|
|
Dtbo365
|
107 |
24K |
0 |
21/03/23 |
21/03/23 |
ASX - By Stock
|
107
|
24K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
SPL7013 and COVID
|
|
Dtbo365
|
56 |
14K |
2 |
17/03/23 |
17/03/23 |
ASX - By Stock
|
56
|
14K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Interim Report and Half-Year Financial Results
|
|
Dtbo365
|
47 |
12K |
0 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
47
|
12K
|
0
|
|
ASX - By Stock
|
SPL Biotech |
Re:
Closing my HC account
|
|
Dtbo365
|
31 |
9.7K |
1 |
23/02/23 |
23/02/23 |
ASX - By Stock
|
31
|
9.7K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Post viral load reduction results
|
|
Dtbo365
|
5 |
1.2K |
4 |
19/02/23 |
19/02/23 |
ASX - By Stock
|
5
|
1.2K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Change in substantial holding
|
|
Dtbo365
|
16 |
4.1K |
2 |
10/02/23 |
10/02/23 |
ASX - By Stock
|
16
|
4.1K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Are representations re Astodrimer for BV now approved
|
|
Dtbo365
|
15 |
3.6K |
2 |
06/02/23 |
06/02/23 |
ASX - By Stock
|
15
|
3.6K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VIRALEZE Post-Market Clinical Study in COVID-19 Patients
|
|
Dtbo365
|
54 |
13K |
0 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
54
|
13K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VIRALEZE Post-Market Clinical Study in COVID-19 Patients
|
|
Dtbo365
|
54 |
13K |
0 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
54
|
13K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Response to ASX Query Letters
|
|
Dtbo365
|
32 |
10K |
0 |
14/01/23 |
14/01/23 |
ASX - By Stock
|
32
|
10K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Response to ASX Query Letters
|
|
Dtbo365
|
32 |
10K |
2 |
14/01/23 |
14/01/23 |
ASX - By Stock
|
32
|
10K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma receives $7.1M R&D tax incentive refund
|
|
Dtbo365
|
22 |
8.2K |
6 |
27/12/22 |
27/12/22 |
ASX - By Stock
|
22
|
8.2K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Trading Halt
|
|
Dtbo365
|
37 |
10K |
0 |
14/12/22 |
14/12/22 |
ASX - By Stock
|
37
|
10K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Trading Halt
|
|
Dtbo365
|
37 |
10K |
0 |
14/12/22 |
14/12/22 |
ASX - By Stock
|
37
|
10K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Trading Halt
|
|
Dtbo365
|
37 |
10K |
2 |
13/12/22 |
13/12/22 |
ASX - By Stock
|
37
|
10K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
UK Post-market Clinical Study of VIRALEZE™ Planned
|
|
Dtbo365
|
16 |
4.7K |
0 |
06/12/22 |
06/12/22 |
ASX - By Stock
|
16
|
4.7K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
UK Post-market Clinical Study of VIRALEZE™ Planned
|
|
Dtbo365
|
16 |
4.7K |
0 |
30/11/22 |
30/11/22 |
ASX - By Stock
|
16
|
4.7K
|
0
|
|